Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq:
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) — Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Fireside chat
Date: Tuesday, November 10, 2026
Time: 3:30 PM – 3:55 PM ET
Stifel 2026 Healthcare Conference
Format: 1×1 Meetings
Date: Wednesday, November 11, 2026
2026 Jefferies Global Healthcare Conference in London
Format: 1×1 Meetings
Date: Monday, November 16 – Wednesday, November 18, 2026
The webcast of the Guggenheim fireside chat will be available in the “Events & Presentations” section of Attovia’s website at https://investors.attovia.com. A replay of the webcast will be available for approximately 90 days following the conference.
About Attovia Therapeutics, Inc.
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.
Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.
Investor and Media Contact
Attovia Therapeutics
ir@attovia.com
PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media gallery
